1
NR 565 Advanced Pharmacology Final Exam
Review Chamberlain University 120
Questions and Answers Actual Exam
2026/2027 Complete Exam-Style Questions
with Detailed Rationales | 100% Verified |
Pass Guaranteed – A+ Graded
Part I: Pharmacokinetics, Pharmacodynamics & Prescribing
Principles (Questions 1-20)
Q1: A patient is taking a drug that is highly protein-bound at
98%. A new medication is prescribed that is also highly protein-
bound at 95%. What is the primary pharmacokinetic concern
when these two medications are combined?
A. Decreased bioavailability of both drugs
B. Increased risk of drug toxicity due to displacement from
protein binding sites [CORRECT]
C. Accelerated first-pass metabolism in the liver
D. Enhanced renal elimination of the unbound drug fraction
Correct Answer: B
Rationale: The best answer is B because when two highly
protein-bound drugs compete for the same binding sites, one
,2
drug can displace the other, suddenly increasing the free, active
fraction of the displaced drug and potentially leading to toxicity.
This matches the pharmacological principle that protein binding
displacement significantly alters drug availability at the target
site.
Q2: When prescribing a medication with a very narrow
therapeutic index, which pharmacokinetic parameter is most
critical for the APRN to monitor to ensure both efficacy and
safety?
A. Half-life
B. Bioavailability
C. Steady-state plasma concentration [CORRECT]
D. Volume of distribution
Correct Answer: C
Rationale: This choice is correct because drugs with a narrow
therapeutic index require precise dosing to maintain steady-state
plasma concentrations within a tight window to avoid
subtherapeutic effects or toxicity. This aligns with NR565
curriculum emphasizing therapeutic drug monitoring for narrow-
index drugs like vancomycin or lithium.
Q3: An APRN is reviewing a patient's pharmacogenomic test
results before starting therapy with codeine. The patient is
,3
identified as a CYP2D6 ultra-rapid metabolizer. What is the
most appropriate prescribing action?
A. Prescribe codeine at a lower than standard dose
B. Avoid prescribing codeine and select an alternative analgesic
[CORRECT]
C. Prescribe codeine at the standard adult dose
D. Add a CYP2D6 inhibitor to the regimen
Correct Answer: B
Rationale: The best answer is B because ultra-rapid metabolizers
convert codeine to morphine at a much faster and higher rate,
leading to a significant risk of life-threatening respiratory
depression even at standard doses. This aligns with NR565
curriculum and FDA black box warnings on codeine
pharmacogenomics.
Q4: Which of the following cytochrome P450 enzymes is most
commonly involved in drug metabolism interactions and is
specifically induced by rifampin?
A. CYP1A2
B. CYP2C9
C. CYP2D6
D. CYP3A4 [CORRECT]
Correct Answer: D
, 4
Rationale: This choice is correct because CYP3A4 is the most
abundant CYP enzyme in the liver and intestines, responsible for
metabolizing a vast number of drugs, and rifampin is a potent
inducer of this enzyme. This matches the pharmacological
principle that CYP3A4 induction leads to significantly
decreased concentrations of many concurrent medications.
Q5: A patient with severe hepatic impairment requires a
medication that undergoes extensive first-pass metabolism. How
should the APRN adjust the prescribing approach for this drug?
A. Increase the oral dose to bypass the damaged liver tissue
B. Decrease the oral dose because less drug is metabolized
before reaching systemic circulation [CORRECT]
C. Switch to an extended-release formulation to delay
metabolism
D. Administer the medication with food to enhance first-pass
extraction
Correct Answer: B
Rationale: The best answer is B because severe hepatic
impairment reduces the liver's metabolic capacity, meaning a
larger fraction of the orally administered drug survives the first
pass and reaches systemic circulation, increasing the risk of
toxicity. This matches the pharmacological principle of altered
first-pass kinetics in liver disease.
NR 565 Advanced Pharmacology Final Exam
Review Chamberlain University 120
Questions and Answers Actual Exam
2026/2027 Complete Exam-Style Questions
with Detailed Rationales | 100% Verified |
Pass Guaranteed – A+ Graded
Part I: Pharmacokinetics, Pharmacodynamics & Prescribing
Principles (Questions 1-20)
Q1: A patient is taking a drug that is highly protein-bound at
98%. A new medication is prescribed that is also highly protein-
bound at 95%. What is the primary pharmacokinetic concern
when these two medications are combined?
A. Decreased bioavailability of both drugs
B. Increased risk of drug toxicity due to displacement from
protein binding sites [CORRECT]
C. Accelerated first-pass metabolism in the liver
D. Enhanced renal elimination of the unbound drug fraction
Correct Answer: B
Rationale: The best answer is B because when two highly
protein-bound drugs compete for the same binding sites, one
,2
drug can displace the other, suddenly increasing the free, active
fraction of the displaced drug and potentially leading to toxicity.
This matches the pharmacological principle that protein binding
displacement significantly alters drug availability at the target
site.
Q2: When prescribing a medication with a very narrow
therapeutic index, which pharmacokinetic parameter is most
critical for the APRN to monitor to ensure both efficacy and
safety?
A. Half-life
B. Bioavailability
C. Steady-state plasma concentration [CORRECT]
D. Volume of distribution
Correct Answer: C
Rationale: This choice is correct because drugs with a narrow
therapeutic index require precise dosing to maintain steady-state
plasma concentrations within a tight window to avoid
subtherapeutic effects or toxicity. This aligns with NR565
curriculum emphasizing therapeutic drug monitoring for narrow-
index drugs like vancomycin or lithium.
Q3: An APRN is reviewing a patient's pharmacogenomic test
results before starting therapy with codeine. The patient is
,3
identified as a CYP2D6 ultra-rapid metabolizer. What is the
most appropriate prescribing action?
A. Prescribe codeine at a lower than standard dose
B. Avoid prescribing codeine and select an alternative analgesic
[CORRECT]
C. Prescribe codeine at the standard adult dose
D. Add a CYP2D6 inhibitor to the regimen
Correct Answer: B
Rationale: The best answer is B because ultra-rapid metabolizers
convert codeine to morphine at a much faster and higher rate,
leading to a significant risk of life-threatening respiratory
depression even at standard doses. This aligns with NR565
curriculum and FDA black box warnings on codeine
pharmacogenomics.
Q4: Which of the following cytochrome P450 enzymes is most
commonly involved in drug metabolism interactions and is
specifically induced by rifampin?
A. CYP1A2
B. CYP2C9
C. CYP2D6
D. CYP3A4 [CORRECT]
Correct Answer: D
, 4
Rationale: This choice is correct because CYP3A4 is the most
abundant CYP enzyme in the liver and intestines, responsible for
metabolizing a vast number of drugs, and rifampin is a potent
inducer of this enzyme. This matches the pharmacological
principle that CYP3A4 induction leads to significantly
decreased concentrations of many concurrent medications.
Q5: A patient with severe hepatic impairment requires a
medication that undergoes extensive first-pass metabolism. How
should the APRN adjust the prescribing approach for this drug?
A. Increase the oral dose to bypass the damaged liver tissue
B. Decrease the oral dose because less drug is metabolized
before reaching systemic circulation [CORRECT]
C. Switch to an extended-release formulation to delay
metabolism
D. Administer the medication with food to enhance first-pass
extraction
Correct Answer: B
Rationale: The best answer is B because severe hepatic
impairment reduces the liver's metabolic capacity, meaning a
larger fraction of the orally administered drug survives the first
pass and reaches systemic circulation, increasing the risk of
toxicity. This matches the pharmacological principle of altered
first-pass kinetics in liver disease.
